Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $30.7 million.

  • Enanta Pharmaceuticals' Accumulated Expenses fell 10.89% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 10.89%. This contributed to the annual value of $30.7 million for FY2025, which is 10.89% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Accumulated Expenses stood at $30.7 million, which was up 10.65% from $27.8 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Accumulated Expenses' 5-year high stood at $36.7 million during Q2 2023, with a 5-year trough of $15.2 million in Q4 2022.
  • Its 3-year average for Accumulated Expenses is $31.5 million, with a median of $32.7 million in 2024.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Accumulated Expenses tumbled by 42.95% in 2022 and then soared by 140.80% in 2023.
  • Enanta Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $26.6 million in 2021, then tumbled by 42.95% to $15.2 million in 2022, then skyrocketed by 140.80% to $36.5 million in 2023, then declined by 10.32% to $32.7 million in 2024, then fell by 10.89% to $30.7 million in 2025.
  • Its Accumulated Expenses stands at $30.7 million for Q3 2025, versus $27.8 million for Q2 2025 and $30.7 million for Q1 2025.